AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other research analysts also recently weighed in on AMAG. Cowen and Company restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Cantor Fitzgerald restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. Barclays PLC restated a “hold” rating and issued a $25.00 target price on shares of AMAG Pharmaceuticals in a research note on Monday, May 15th. Finally, Deutsche Bank AG set a $24.00 target price on shares of AMAG Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, July 7th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating to the company. AMAG Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $28.09.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded down 3.000% during trading on Thursday, hitting $16.975. 67,457 shares of the company were exchanged. AMAG Pharmaceuticals has a 12 month low of $16.00 and a 12 month high of $36.83. The company’s market capitalization is $599.01 million. The company has a 50-day moving average of $19.12 and a 200-day moving average of $20.89.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.45 earnings per share. Analysts forecast that AMAG Pharmaceuticals will post ($0.41) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers AMAG Pharmaceuticals, Inc. (AMAG) to Hold” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/10/bidaskclub-lowers-amag-pharmaceuticals-inc-amag-to-hold.html.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares in the company, valued at approximately $566,720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. increased its position in AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after buying an additional 4,988,054 shares during the period. Vanguard Group Inc. boosted its stake in shares of AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after buying an additional 176,832 shares during the period. State Street Corp boosted its stake in shares of AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after buying an additional 1,082,366 shares during the period. LSV Asset Management boosted its stake in shares of AMAG Pharmaceuticals by 34.0% in the first quarter. LSV Asset Management now owns 1,685,098 shares of the specialty pharmaceutical company’s stock worth $37,998,000 after buying an additional 427,238 shares during the period. Finally, Acadian Asset Management LLC boosted its stake in shares of AMAG Pharmaceuticals by 777.8% in the first quarter. Acadian Asset Management LLC now owns 1,226,690 shares of the specialty pharmaceutical company’s stock worth $27,659,000 after buying an additional 1,086,937 shares during the period.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.